Status:

COMPLETED

Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

XXB750 in Healthy Participants

Eligibility:

All Genders

18-50 years

Phase:

PHASE1

Brief Summary

This study was a randomized, participant and investigator-blinded, placebo-controlled, single-ascending dose study, consisting of 9 sequential dose cohorts (1 mg, 3 mg, 10 mg, 30 mg, 60 mg, 120 mg, 24...

Detailed Description

Eligible healthy participants with normal blood pressure (SBP: 110-139 mmHg; DBP: 70-89 mmHg) were randomized into dose cohorts 1 - 240 mg. Eligible healthy participants with elevated blood pressure (...

Eligibility Criteria

Inclusion

  • Healthy male and female participants age 18 to 50 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
  • Participants must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 32 kg/m2. BMI = Body weight (kg) / \[Height (m)\]2
  • For ethnic Japanese cohort: participants must be defined as being of first, second or third generation ethnic origin, with each set of parents qualifying as Japanese under the prior generation.

Exclusion

  • Any surgical or medical condition which significantly altered the distribution, metabolism, or excretion of drugs, or which jeopardized the participant's participation in the study.
  • Known history or current clinically significant arrhythmias.
  • Women of child-bearing potential were excluded from this study.

Key Trial Info

Start Date :

July 29 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 31 2023

Estimated Enrollment :

77 Patients enrolled

Trial Details

Trial ID

NCT06558097

Start Date

July 29 2020

End Date

March 31 2023

Last Update

August 16 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Novartis Investigative Site

Cypress, California, United States, 90630